【Abstract】 Objective To explore the features of Ki-ras mutations at codon 12 in Chinese patients of pancreatic cancer and to compare these features with those in Western countries. Methods Fifty-nine samples were collected during operations for pancreatic adenocarcinoma in our hospital from December 1989 to November 1997. The patients, age ranged from 30 to 73 years 〔(55.5±10.4) years〕,with 38 males and 21 female. TNM staging of the patients: stage Ⅰ(n=4); stage Ⅱ(n=8), stage Ⅲ(n=42),stage Ⅳ(n=5). PCR was used to amplify target gene and Dot blot hybridization for detecting Ki-ras mutations at codon 12 was performed in fifty-nine specimens of Chinese pancreatic cancer. The data of Ki-ras mutations at codon 12 from Western countries were gotten by Medline system. Results Ki-ras mutation at codon 12 was detected in 76.3% of the patients in this group. The frequency of double mutation of Ki-ras at codon 12 in this group (15.6%) was highest than that in western countries. Our results were compared with those reported in Western countries. The results suggested that there were the significant differences in the substitution of Ki-ras mutations at codon 12 and in the ratio of transition to transversion in pancreatic cancer among various countries. Conclusion Ki-ras mutations at codon 12 is frequent in Chinese pancreatic cancer, and a gene component to pancreatic cancer may be different among various countries. In addition, the effect of Ki-ras mutations at codon 12 on prognosis of patients with pancreatic cancer is different in various countries.
目的总结胰腺血管活性肠肽瘤(VIPoma)的临床特点并探讨其诊治方法。 方法回顾性分析1991年11月至2010年2月期间我院收治的3例VIPoma患者的临床资料。 结果3例均有周期性发作水样泻、低钾血症和低或无胃酸。有2例血浆血管活性肠肽值显著升高。B超及CT发现3例肿瘤均位于胰腺内,其中1例肝转移,1例怀疑肝转移。3例均行手术治疗。1例肿瘤位于胰头部行胰十二指肠切除术,随访3年无肿瘤复发;1例肿瘤位于胰头颈部及肝脏多发转移灶,行胰腺头颈部切除及肝脏转移结节摘除术,术后4个月腹泻症状复发,证实肝脏多发转移灶,又先后3次手术,于第1次手术后3.5年死于电解质紊乱;另1例术中发现肿瘤位于胰头部无法切除,肝脏多发转移灶,摘除1枚肝脏结节病理确认为转移癌,术后间断应用奥曲肽,术后2.5年仍在随访中。 结论VIPoma首选的治疗方法是手术切除肿瘤。恶性肿瘤即使无法根治手术,也应该姑息性切除和间断应用奥曲肽,以改善患者生活质量。
【Abstract】ObjectiveTo evaluate the relationships between the transporters BSEP, MRP2, MDR3 and cholesterol calculus formation. MethodsTwenty hepatic tissue specimens were taken from consented patients with cholesterol calculus during intraoperative liver biopsy, of which ten were taken from patients without cholesterol calculus. RNA of liver tissue from all the samples was extracted and ultraviolet spectrophotometry was used to measure the content and purity of it. The mRNA and protein expressions of BSEP, MRP2 and MDR3 were determined by reverse transcriptionpolymerase chain reaction (RTPCR) and Western blot analysis, respectively. ResultsRTPCR showed that the mRNA expressions of BSEP, MRP2 and MDR3 in liver were significantly lower in patients with cholesterol calculus (0.47±0.18, 1.12±0.39 and 1.02±0.24) than those in the liver of patients without calculus (0.90±0.42, 2.48±0.89 and 1.94±0.80),P<0.01. And Western blot also showed the protein expressions of these transporters were significantly lower in patients with cholesterol calculus (90.16±18.82, 45.43±22.77 and 61.08±14.77) than those in the liver of patients without calculus (186.17±4.34, 160.47±30.19 and 100.84±15.44). ConclusionThe decreased expression of BSEP, MRP2 and MDR3 may correlate with the formation of cholesterol calculus.